Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|12|4|391-401

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.4, 2012-04, pp. : 391-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nilotinib: In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

By  

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-09 ,pp. : 755-767

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

By Breccia Massimo   Alimena Giuliana  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2075-2087

Informa Healthcare

Access to resources Recommend Favorite